Journal for ImmunoTherapy of Cancer (Nov 2020)
696 Brentuximab vedotin, a CD30-directed antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo
Abstract
No abstracts available.
Journal for ImmunoTherapy of Cancer (Nov 2020)